



**CareSource considers Zepatier (grazoprevir/elbasvir) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.**

DATE	ACTION/DESCRIPTION
05/09/2017	New policy for Zepatier created. Alternative products were indicated. Hep B test requirement was added. Drug and alcohol screens for 3 consecutive months required for all regardless of abuse history. Evidence of liver fibrosis exceptions was expanded. Reauthorization requirement during the post-treatment period and documented reason of treatment failure were added.
06/08/2017	Fibrosis stage 2 and above covered
11/22/2017	Medication status changed to non-preferred. Substance abuse program information is no longer required. Trial of preferred agent is required. Reauthorization criteria were removed. Criterion on absence of moderate to severe liver impairment was added.
12/17/2017	Criterion of “life expectancy not less than one year due to non-liver related comorbidities” removed from criteria and added in a form of the note. Hepatitis B testing is no longer required.
12/21/2017	Fibrosis score requirement was removed.
05/01/2019	Sofosbuvir/velpatasvir (generic for Epclusa) added to trials.
02/24/2022	Lowered age and added weight requirement. Removed urine drug screen requirement. Updated references. Transferred to new template

References:

1. Zepatier [package insert]. Merck Sharp & Dohme Corp: Whitehouse Station, NJ; December 2021.
2. American Association for the Study of Liver Diseases and the Infectious Diseases Society of America (AASLD) and Infectious Diseases Society of America (IDSA). HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C; 2021. Available at: <https://www.hcvguidelines.org/>.
3. Hepatitis C Information | Division of Viral Hepatitis | CDC; July 2020. Retrieved from <https://www.cdc.gov/hepatitis/hcv/index.htm>.

Effective date: 07/01/2022  
 Revised date: 02/24/2022

## Appendix. Treatment Duration

<b>Genotype and Population</b>	<b>Treatment</b>	<b>Duration</b>
Genotype 1a: Treatment-naïve or PegIFN/RBV experienced <sup>1</sup> without baseline NS5A polymorphisms <sup>2</sup>	Zepatier	12 weeks
Genotype 1a: Treatment-naïve or PegIFN/RBV experienced <sup>1</sup> with baseline NS5A polymorphisms <sup>2</sup>		